G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$7.15 USD
0.00 (0.00%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $7.15 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
Brokerage Reports
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 241 - 260 ( 361 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Global Lerociclib Out-Licensing Agreement with EQRx
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
A Synopsis of Our Recent Webinar with Management
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Reminder to Register for Our Call with CEO and CMO on July 8 at 12PM ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Co-promotion Agreement Between G1 and Boehringer Ingelheim for Trilaciclib Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Boehringer Commercial Team Called in for Trila
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Register Now to Join Our Call with CEO and CMO on July 8 at 12PM ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Co-Promotion Agreement is a Sign of Confidence for Timely Approval
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Lero Rights in Asia-Pacific Go to Genor for $6M
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Deal Announced With Genor Biopharma for Lerociclib in the Asia-Pacific Region
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E